Use of dronabinol for cannabis dependence: Two case reports and review

American Journal on Addictions

Volumn 17, Issue 2, 2008, Pages 161-164

  Levin, Frances R ^a   Kleber, Herbert D ^b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DRONABINOL; VALPROATE SEMISODIUM; VENLAFAXINE;

ADULT; ALCOHOL CONSUMPTION; ANAMNESIS; ARTICLE; CANNABIS ADDICTION; CASE REPORT; CLINICAL FEATURE; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; HUMAN; MALE; NAUSEA; VOMITING;

ADULT; ALCOHOLISM; AMBULATORY CARE; BENZHYDRYL COMPOUNDS; CANNABINOIDS; COMORBIDITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; MALE; MARIJUANA ABUSE; PSYCHOTROPIC DRUGS; SUBSTANCE WITHDRAWAL SYNDROME; TETRAHYDROCANNABINOL; TREATMENT OUTCOME; VALPROIC ACID;

EID: 41949083220     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1080/10550490701861177     Document Type: Article

References (28)

1. Office of National Drug Control Policy. National Drug Control Strategy, February 2002. Available at: http://www.whitehousedrugpolicy.gov/publications/ policy/03ndcs/table21.html. Accessed January 27, 2003.
2. SAMSHA: The National Survey on Drug Use and Health, 2006; http://oas.samhsa.gov/nsduh/2k6nsduh/2k6results.cfm, accessed March 3, 2008.
3. Monitoring the Future. http://monitoringthefuture.org/pubs/monographs/ voll2006.pdf, accessed March 3, 2008.
4. Stephens RS, Roffman RA, Simpson EE. Treating adult marijuana dependence: a test of the relapse prevention model. J Consult Clin Psychol. 1994;62:92-99.
5. Stephens RS, Roffman RA, Curtin L. Comparison of extended versus brief treatments for marijuana use. J Consult Clin Psychol. 2000;68:898-908.
6. Budney AJ, Higgins ST, Radonovich KJ, Novy PL. Adding voucher-based incentives to coping skills and motivational enhancement improves outcomes during treatment for marijuana dependence. J Consult Clin Psychol. 2000;68:1051-1061.
7. Dennis M, Titus JC, Diamond G, et al. The Cannabis Youth Treatment (CYT) experiment: rationale, study design and analysis plans. Addiction. 2002;97 (Suppl. 1):16-34.
8. Diamond G, Godley SH, Liddle HA, et al. Five outpatient treatment models for adolescent marijuana use: a description of the Cannabis Youth Treatment Interventions. Addiction. 2002;97 (Suppl. 1):70-83.
9. French MT, Roebuck MC, Dennis ML, et al. The economic cost of outpatient marijuana treatment for adolescents: findings from a multisite field experiment. Addiction. 2002;97 (Suppl. 1):84-97.
10. Dennis M, Godley SH, Diamond G, et al. The Cannabis Youth Treatment (CYT) study: main findings from two randomized trials. J Subst Abuse Treat. 2004;27:197-213.
11. Stephens RS, Babor TF, Kadden R, Miller M. The Marijuana Treatment Project: rationale, design and participant characteristics. Addiction. 2002;97 (Suppl. 1):109-124.
12. Steinberg KL, Roffman RA, Carroll KM, et al. Tailoring cannabis dependence treatment for a diverse population. Addiction. 2002;97 (Suppl. 1):135-142.
13. Cornelius JR, Salloum IM, Haskett RF, et al. Fluoxetine versus placebo for the marijuana use of depressed alcoholics. Addict Behav. 1999;24:111-114.
14. Levin FR, McDowell D, Evans SM, et al. Pharmacotherapy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium. Am J Addict. 2004;13:21-32.
15. Kouri EM, Pope HG Jr. Abstinence symptoms during withdrawal from chronic marijuana use. Exp Clin Psychopharmacol. 2000;8:483-492.
16. Wiesbeck GA, Schuckit MA, Kalmijn JA, Tipp JE, Bucholz KK, Smith TL. An evaluation of the history of a marijuana withdrawal syndrome in a large population. Addiction. 1996;91:1469-1478.
17. Mendelson JH, Mello NK, Lex BW, Bavli S. Marijuana withdrawal syndrome in a woman. Am J Psychiatry. 1984;141:1289-1290.
18. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW. Abstinence symptoms following smoked marijuana in humans. Psychopharmacology (Berl). 1999;141:395-404.
19. Hart CL, Haney M, Ward AS, Fischman MW, Foltin RW. Effects of oral THC maintenance on smoked marijuana self-administration. Drug Alcohol Depend. 2002;67:301-309.
20. Haney M, Hart CL, Vosburg SK, et al. Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology. 2004;29:158-170.
21. Budney AJ, Moore BA, Vandrey RG, Hughes JR. The time course and significance of cannabis withdrawal. J Abnorm Psychol. 2003;112:393-402.
22. Haney M, Ward AS, Comer SD, Hart CL, Foltin RW, Fischman MW. Bupropion SR worsens mood during marijuana withdrawal in humans. Psychopharmacology (Berl). 2001;155:171-179.
23. Haney M, Hart CL, Ward AS, Foltin RW. Nefazodone decreases anxiety during marijuana withdrawal in humans. Psychopharmacology (Berl). 2003;165:157-165.
24. Budney AJ, Vandrey RG, Hughes JR, Moore BA, Bahrenburg B. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend. 2007;86:22-29.
25. Chait LD, Zacny JP. Reinforcing and subjective effects of oral delta 9-THC and smoked marijuana in humans. Psychopharmacology (Berl). 1992;107:255-262.
26. Kirk JM, Doty P, De Wit H. Effects of expectancies on subjective responses to oral delta9-tetrahydrocannabinol. Pharmacol Biochem Behav. 1998;59:287-293.
27. Calhoun SR, Galloway GP, Smith DE. Abuse potential of dronabinol (Marinol). J Psychoactive Drugs. 1998;30:187-196.
28. Donovan SJ, Stewart JW, Nunes EV, et al. Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design. Am J Psychiatry. 2000;157:818-820.